492.05

+3.23%↑

SANES

10.542

+2.15%↑

SAF

315.7

+0.7%↑

BBVA

19.645

+2.16%↑

BNP

90.7

+2.31%↑

492.05

+3.23%↑

SANES

10.542

+2.15%↑

SAF

315.7

+0.7%↑

BBVA

19.645

+2.16%↑

BNP

90.7

+2.31%↑

492.05

+3.23%↑

SANES

10.542

+2.15%↑

SAF

315.7

+0.7%↑

BBVA

19.645

+2.16%↑

BNP

90.7

+2.31%↑

492.05

+3.23%↑

SANES

10.542

+2.15%↑

SAF

315.7

+0.7%↑

BBVA

19.645

+2.16%↑

BNP

90.7

+2.31%↑

492.05

+3.23%↑

SANES

10.542

+2.15%↑

SAF

315.7

+0.7%↑

BBVA

19.645

+2.16%↑

BNP

90.7

+2.31%↑

Home・Akcijų sąrašas・AB Science SA

AB Science SA

Atidarymo kaina

1.178 -0.17

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.158

Max

1.21

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-5.2M
Pardavimai	515K
Pelno marža	-1,005.243
Darbuotojai	36
EBITDA	-2.5M

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	78M
Ankstesnė atidarymo kaina	1.35
Ankstesnė uždarymo kaina	1.178

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.426 / 1.448 Palaikymas ir pasipriešinimas

AB Science SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB: Higher Energy Prices to Raise Production, Consumer Costs

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

2026-04-10 00:00; UTC

Svarbiausios naujienos

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

2026-04-10 00:00; UTC

Svarbiausios naujienos

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

2026-04-09 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

2026-04-09 23:34; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

2026-04-09 23:14; UTC

Rinkos pokalbiai

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

2026-04-09 23:14; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-09 23:07; UTC

Rinkos pokalbiai

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

2026-04-09 22:54; UTC

Rinkos pokalbiai

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

2026-04-09 22:31; UTC

Svarbiausios naujienos

Trump on Truth Social: 'That Is Not the Agreement We Have!'

2026-04-09 22:31; UTC

Svarbiausios naujienos

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

2026-04-09 20:57; UTC

Svarbiausios naujienos

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

2026-04-09 20:55; UTC

Uždarbis

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

2026-04-09 20:55; UTC

Uždarbis

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

2026-04-09 20:55; UTC

Uždarbis

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

2026-04-09 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-04-09 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-09 20:40; UTC

Įsigijimai, susijungimai, perėmimai

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

2026-04-09 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

2026-04-09 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Rowan Digital Infrastructure Announces Strategic Recapitalization

2026-04-09 20:25; UTC

Įsigijimai, susijungimai, perėmimai

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

2026-04-09 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-09 19:30; UTC

Svarbiausios naujienos

How Digital Currencies Have Helped Iran -- WSJ

Akcijų palyginimas

Kainos pokytis

AB Science SA Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių AB Science SA akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.426 / 1.448Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.